


C L A I M S

1. A compound of formula




5 wherein m represents 1, 2 or 3;
 each R¹ independently represents a hydrogen or halogen atom;
 one of R² and R³ represents halogen, nitro, amino, hydroxyl, or a group
 selected from (i) C₁-C₆ alkyl optionally substituted by at least one halogen atom,
 (ii) C₃-C₈ cycloalkyl, (iii) C₁-C₆ alkoxy optionally substituted by at least one halogen
 10 atom, and (iv) C₃-C₈ cycloalkyloxy, and the other of R² and R³ represents a hydrogen or
 halogen atom;
 n represents 0, 1 or 2; and
 R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally
 substituted by at least one substituent selected from hydroxyl, halogen and C₁-C₆ alkoxy;
 15 or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein m is 1.

3. A compound according to claim 1 or claim 2, wherein R³ represents a hydrogen
 20 atom.

4. A compound according to any one of claims 1 to 3, wherein n is 1.

5. A compound according to claim 4, which has the following stereochemistry:



5

6. A compound according to any one of claims 1 to 5, wherein R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by at least one hydroxyl group.

10 7. A compound according to claim 1, wherein

m represents 1;

each R¹ represents a hydrogen atom;

one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;

15 n is 0, 1 or 2; and

R⁴ and R⁵ each independently represent a hydrogen atom or a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

8. A compound according to claim 1, wherein

20 m represents 1;

each R¹ represents a hydrogen atom;

one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;

n is 0, 1 or 2; and

one of R⁴ and R⁵ represents a hydrogen atom or -CH₃ and the other of R⁴ and R⁵ represents a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

5 9. A compound being selected from any one of:

2-Chloro-5-[(3S)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3S)-3-hydroxy-4-(ethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

10 2-Chloro-5-[(3S)-3-hydroxy-4-(1-methylethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3R)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

15 2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

20 2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

25 2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

5 2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

10 2-Chloro-5-[(1R)-2-(ethylamino)-1-hydroxyethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(1R)-1-hydroxy-2-[(3-hydroxypropyl)amino]ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

15 2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

20 2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,


2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide benzoic acid salt,

25 2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

and all pharmaceutically acceptable salts and solvates thereof.


10. A process for the preparation of a compound according to claim 1, which comprises:

(i) when n is 0, reacting a compound of formula




wherein m, R¹, R² and R³ are as defined in formula (I), with a compound of formula (III), HNR⁴R⁵, wherein R⁴ and R⁵ are as defined in formula (I); or

5 (ii) when n is 1, reacting a compound of formula




wherein m, R¹, R² and R³ are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

10 (iii) when n is 2, reacting a compound of formula



wherein L¹ is a leaving group and m, R¹, R² and R³ are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

- 5 (iv) when n is 1, reacting a compound of formula



wherein L² is a leaving group and m, R¹, R² and R³ are as defined in formula (I), with a compound of formula (III) as defined in (i) above;

- 10 and optionally after (i), (ii) (iii) or (iv) carrying out one or more of the following:

- converting the compound obtained to a further compound of formula (I)
- forming a pharmaceutically acceptable salt or solvate of the compound.

11. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. A process for the preparation of a pharmaceutical composition as claimed in claim 11 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in any one of claims 1 to 9 with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

13. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 for use in therapy.

14. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use 10 in the treatment of rheumatoid arthritis.

15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use 15 in the treatment of an obstructive airways disease.

16. Use according to claim 15, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

20 17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of osteoarthritis.

25 18. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of atherosclerosis.

19. A method of treating rheumatoid arthritis or osteoarthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9.

20. A method of treating an obstructive airways disease which comprises administering
5 to a patient a therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9.